0001001316
false
0001001316
2019-12-08
2019-12-08
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
_____________
FORM
8-K
_____________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
report (Date of earliest event reported): December 8,
2019
TG Therapeutics, Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction
of
Incorporation)
|
001-32639
(Commission File
Number)
|
36-3898269
(IRS
Employer Identification No.)
|
2 Gansevoort Street, 9th Floor
New York, New
York 10014
(Address of
Principal Executive Offices)
(212)
554-4484
(Registrant's
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act.
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act.
☐
Pre-commencement communications pursuant to Rule 14d-2b under the
Exchange Act.
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act.
Title
of Class
|
Trading
Symbol(s)
|
Exchange
Name
|
Common Stock,
par value $0.001
|
TGTX
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR §240.12b-2). Emerging growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On
December 8, 2019, TG Therapeutics, Inc. (the “Company”)
issued a press release announcing data from the Phase 1/2 study of
the triple combination of ublituximab (TG-1101), the
Company’s novel glycoengineered anti-CD20 monoclonal
antibody, in combination with umbralisib (TGR-1202), the
Company’s oral, dual inhibitor of PI3K delta and CK1 epsilon,
and venetoclax, in patients with relapsed/refractory chronic
lymphocytic leukemia (CLL). On December 9, 2019, the Company also
announced Phase 1 clinical data for TG-1701, the Company’s
covalently-bound Bruton’s Tyrosine Kinase (BTK) inhibitor, in
patients with relapsed/refractory B-cell malignancies. Both press
releases summarized data presented during the 61st American Society of
Hematology (ASH) Annual Meeting and Exposition. Copies of the
press releases are being filed as Exhibit 99.1 and Exhibit 99.2 and
incorporated in this Item by reference.
Item
9.01 Financial Statements And Exhibits.
(d)
Exhibits.
Press Release,
dated December 8, 2019.
Press Release,
dated December 9, 2019.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
TG Therapeutics, Inc.
(Registrant)
|
|
|
|
|
|
Date:
December 9, 2019
|
By:
|
/s/
Sean A. Power
|
|
|
|
Sean A.
Power
|
|
|
|
Chief
Financial Officer
|
|